SCHEMBL6654010

SCHEMBL6654010

COc1ccc(/C=C(\CC(=O)O)C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.51
RECQL P46063 1/20 0.51
GLO1 Q04760 3/20 0.49
MAPT P10636 3/20 0.49
RAB9A P51151 2/20 0.49
THRB P10828 2/20 0.49
KDM4E B2RXH2 2/20 0.49
NPC1 O15118 1/20 0.49
ATM Q13315 1/20 0.49
CYP1A2 P05177 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 1/20 0.47
AKR1C3 P42330 1/20 0.47
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6654014 1.00 GSK3B (0.51) GSK3BRECQLGLO1MAPTRAB9A
SCHEMBL7617840 0.89 GSK3B (0.50) GSK3BRECQLGLO1MAPTRAB9A
SCHEMBL7934147 0.89 GSK3B (0.50) GSK3BRECQLGLO1MAPTRAB9A
SCHEMBL8153618 0.85 NPC1 (0.59) GSK3BMAPTRAB9ATHRBKDM4E
SCHEMBL8153624 0.85 NPC1 (0.59) GSK3BMAPTRAB9ATHRBKDM4E
SCHEMBL8419202 0.85 MAPT (0.50) GSK3BMAPTRAB9ATHRBKDM4E
SCHEMBL6659979 0.85 MAPT (0.50) GSK3BMAPTRAB9ATHRBKDM4E
SCHEMBL285248 0.85 MAPT (0.50) GSK3BMAPTRAB9ATHRBKDM4E
SCHEMBL6658028 0.84 GSK3B (0.46) GSK3BMAPTRAB9ATHRBKDM4E
SCHEMBL6658026 0.84 GSK3B (0.46) GSK3BMAPTRAB9ATHRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040254241-A1 Enzyme inhibitor; cognition activators KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-12-16 US disclosed
EP-1431280-A1 ARYL SULFAMATE DERIVATIVES Kyowa Hakko Kogyo Co., Ltd (JP) 2004-06-23 EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254241-A1 Enzyme inhibitor; cognition activators SULT1A1, STS, CYP26A1 GSK3B 2607/4885RECQL 2311/4885GLO1 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.